|
|
|
|
| LEADER |
02502nam a2200337 u 4500 |
| 001 |
EB001839561 |
| 003 |
EBX01000000000000001003550 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
180702 r ||| eng |
| 130 |
0 |
|
|a Lipid modification (National Clinical Guideline Centre for Acute and Chronic Conditions (Great Britain))
|
| 245 |
0 |
0 |
|a Lipid modification
|h Elektronische Ressource
|b cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease : final version
|c National Clinical Guideline Centre
|
| 260 |
|
|
|a London
|b National Clinical Guideline Centre
|c 2014, July 2014
|
| 300 |
|
|
|a 1 PDF file (302 pages)
|b illustrations
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Lipids / blood
|
| 653 |
|
|
|a Risk Assessment / methods
|
| 653 |
|
|
|a Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
|
| 653 |
|
|
|a Mass Screening / methods
|
| 653 |
|
|
|a Cardiovascular Diseases / prevention & control
|
| 653 |
|
|
|a Cholesterol, LDL / drug effects
|
| 710 |
2 |
|
|a National Clinical Guideline Centre for Acute and Chronic Conditions (Great Britain)
|
| 710 |
2 |
|
|a National Institute for Health and Care Excellence (Great Britain)
|
| 740 |
0 |
2 |
|a National Clinical Guideline Centre for Acute and Chronic Conditions (Great Britain))
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a NICE clinical guideline
|
| 500 |
|
|
|a Title from PDF cover. - "This guidance is a partial update of NICE clinical guideline 67 (published 2008) and will replace it" --P. 10
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK248067
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a This guideline updates for primary prevention, the NICE technology appraisal, Statins for the prevention of cardiovascular events' (TA94, 2007) and reviews and updates the recommendations made in the NICE guideline Lipid Modification (CG67, 2008) for primary and secondary prevention of cardiovascular disease (CVD). The scope for this guideline was limited to the identification and assessment of CVD risk and to the assessment and modification of lipids in people at risk of CVD, or people with known CVD. The guideline development group wishes to make clear that lipid modification should take place as part of a programme of risk reduction which also include attention to the management of all other known CVD risk factors
|